ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012 in Cancer

ASCO: continuing avastin with 2nd-Line chemo ups survival

Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival and progression-free survival in patients with metastatic colorectal cancer who have progressed after discontinuation of first-line bevacizumab and chemotherapy, according to the results of a phase III study presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy, according to the results of a phase III study presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Dirk Arnold, M.D., from the University Clinic Eppendorf in Hamburg, Germany, and colleagues randomized 820 patients with unresectable, histologically-confirmed mCRC, who had progressed within three months after discontinuation of first-line bevacizumab plus chemotherapy, to receive second-line fluoropyrimidine-based chemotherapy with bevacizumab (2.5 mg/kg/week equivalent; 409 patients) or without bevacizumab (411 patients). The choice of oxaliplatin- or irinotecan-based second-line chemotherapy was dependent on the regimen used in first-line treatment.

The researchers found that the median OS was significantly longer in those receiving bevacizumab and chemotherapy, compared to those receiving only chemotherapy (11.2 versus 9.8 months; hazard ratio [HR], 0.81), as was median PFS (5.7 versus 4.1 months; HR, 0.68). The adverse event profile was similar to previously reported data for bevacizumab and chemotherapy. When compared with historical data from bevacizumab treatment in first- and second-line mCRC treatment, bevacizumab-related adverse events were not increased by continuing treatment beyond progression.

"By simply switching when the cancer progresses and continuing with bevacizumab, we can make second-line treatment even more powerful," Arnold said in a statement. "This finding will likely spur research into other cancer types that are sensitive to both bevacizumab and chemotherapy."

Several authors disclosed to pharmaceutical companies, including Genentech/Roche, the manufacturer of bevacizumab.

More information: Abstract
More Information

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Japan hospital tests powerful breast cancer therapy

A Japanese cancer specialist said Wednesday she has started the world's first clinical trial of a powerful, non-surgical, short-term radiation therapy for breast cancer.

Cancer created 9 minutes ago | popularity not rated yet | comments 0

Small cancer risk following CT scans in childhood and adolescence confirmed

The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...

Cancer created 13 hours ago | popularity not rated yet | comments 0

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

Cancer created 14 hours ago | popularity not rated yet | comments 0

Novel RNA-based classification system for colorectal cancer

A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...

Cancer created 14 hours ago | popularity not rated yet | comments 0

Low radiation scans help identify cancer in earliest stages

A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...

Cancer created 16 hours ago | popularity not rated yet | comments 0


Italy approves law on controversial stem cell therapy

Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill ...

Portland, Ore., rejecting water fluoridation

(AP)—The mayor of Portland, Ore., has conceded defeat in an effort to add fluoride to the city's drinking water.

Mysterious illness kills two in southeast Alabama

(AP)—Alabama health officials say a mysterious respiratory illness has left five people hospitalized and two dead in the southeastern part of the state.

Targeting the X-factor to tackle cardiovascular disease

New research at The University of Nottingham aimed at preventing harmful blood clots associated with heart disease and stroke has recently received a major funding boost from the British Heart Foundation.

Study focuses on new mums' sleepiness and injury risk on the road

New mothers throughout Australia are needed to help QUT sleep researchers investigate whether the disrupted sleep experienced by mothers when caring for their new baby raises the risk of injury while driving.

Study says empathy plays a key role in moral judgments

Is it permissible to harm one to save many? Those who tend to say "yes" when faced with this classic dilemma are likely to be deficient in a specific kind of empathy, according to a report published in the scientific journal ...